TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE)-- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical program ...
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued ...
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies ...
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the Institutional Review Board (“IRB”) at ...
Biosimilar formulation development requires navigating around scientific, regulatory, and legal challenges, according to Sung ...
Peer-reviewed randomized controlled study by People Science and Mimio Health, published in Nature Scientific Reports LOS ANGELES, March 2, 2026 /PRNewswire/ -- People Science today announced the ...
Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo. Based on the encouraging weight loss, as well as the safety and tolerability results ...
Applying DSM criteria in a simple checklist fashion can result in significant clinical mistakes and overmedication, Giovanni A. Fava warns in his latest book, Clinical Judgment in Psychiatry: The ...
Company outlines near-term pharmacokinetic milestones, highlights amorphous formulation strategy, and announces planned global patent filing TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE)-- Inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results